Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2)
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and effectiveness of the use of
intravascular paclitaxel, in addition to standard therapy, for the treatment of arteriovenous
dialysis access fistula stenosis.
A fistulogram will be performed in standard fashion. The diagnostic component will include
evaluation of the inflow artery, arterial anastomosis and full length of the fistula vein or
graft, plus venous return up to the heart. The location, vessel size, lesion diameter and
percent stenosis for each lesion will be recorded. Enrollment and randomization will occur at
this point.
All patients will then receive standard therapy for their stenosis. This will include
intravenous heparin administered in a standard dose of 70 units/kg. Lesions that respond
poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations)
will be stented. Stent selection will be based on clinical setting. Initial stent treatment
will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include
initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
Documentation of location and type of treatment for each lesion treated will be recorded.
Once standard treatment is completed, the operating surgeon will be informed of the results
of randomization: treatment (paclitaxel) or control. For subjects assigned to treatment, the
whole fistula vein outflow segment of the fistula will be treated with paclitaxel.
The full length of the radial artery from 1 cm of its origin to fistula anatomosis will be
treated with paclitaxel. In addition the anastomosis and first 4 cm of the fistula vein will
be treated. Paclitaxel solution treatment of each lesion encountered will be attempted until
the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter
and length of the vessels treated. Maximization of the length of vessel and lesions treated
will be undertaken when there are more lesions than can be accommodated by the 12 mg, 10 ml
dose available.
A 5 F sheath, 20 cm in length, will be used to administer the paclitaxel. This will be
advanced from its distal position in the radial artery over the guidewire so that the tip of
the sheath is in the proximal radial artery.
Prior to removal of the sheath, a final angiographic study of all areas treated is performed
to document patency and lesion appearance. Any additional lesions identified with this study
are then treated appropriately following standard technique.
For the control group, instead of paclitaxel administration, a sham treatment period of 10
minutes is allowed to elapse followed by the performance of the final completion angiogram.
Any additional lesions identified with this study are then treated appropriately following
standard technique.
All patients will follow the same follow up evaluation schedule